Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors

International Journal of Clinical Oncology

Volumn 14, Issue 4, 2009, Pages 307-314

  Doi, Toshihiko ^a   Ohtsu, Atsushi ^a   Tahara, Makoto ^a   Tamura, Tomohide ^b   Shirao, Kuniaki ^c   Yamada, Yasuhide ^b   Otani, Satoru ^d   Yang, Bing Bing ^e   Ohkura, Masayuki ^d   Ohtsu, Tomoko ^d  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c OITA UNIVERSITY   (Japan)

^d Takeda Bio Development Center Ltd   (Japan)

^e AMGEN INC   (United States)

Author keywords

Epidermal growth factor receptor; Panitumumab; Pharmacokinetics; Safety

Indexed keywords

ACETYLSALICYLIC ACID; PANITUMUMAB;

ACNE; ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COLON TUMOR; COLORECTAL CANCER; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED STUDY; DERMATITIS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; EDEMA; ERYTHEMA; ESOPHAGUS TUMOR; FATIGUE; FEMALE; FEVER; FLUSHING; HAND FOOT SYNDROME; HEAD AND NECK TUMOR; HOT FLUSH; HUMAN; HYPERTRICHOSIS; HYPOMAGNESEMIA; JAPANESE; MALE; MAXIMUM TOLERATED DOSE; NAIL DISEASE; NAUSEA; OVARY TUMOR; PARONYCHIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RECTUM TUMOR; SIDE EFFECT; SKIN FISSURE; SKIN PRURITUS; SKIN TOXICITY; STOMACH TUMOR; STOMATITIS; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; JAPAN; MALE; MIDDLE AGED; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS; TREATMENT OUTCOME;

EID: 69249187806     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-008-0855-2     Document Type: Article

References (29)

1. C.L. Arteaga 2001 The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia J Clin Oncol 19 32S 40S
2. W.J. Gullick 1991 Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers Br Med Bull 47 87 98
3. J. Mendelsohn J. Baselga 2003 Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J Clin Oncol 21 2787 2799
4. K.A. Foon X.D. Yang L.M. Weiner 2004 Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody Int J Radiat Oncol Biol Phys 58 984 990
5. A. Jakobovits 1995 Production of fully human antibodies by transgenic mice Curr Opin Biotechnol 6 561 566
6. A. Jakobovits R.G. Amado X. Yang 2007 From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice Nat Biotechnol 25 1134 1143
7. E.K. Rowinsky G.H. Schwartz J.A. Gollob 2004 Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer J Clin Oncol 22 3003 3015
8. L.M. Weiner A.S. Belldegrun J. Crawford 2008 Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies Clin Cancer Res 14 502 508
9. T.J.J. Lynch E.S. Kim B. Eaby 2007 Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management Oncologist 12 610 621
10. Berlin J, Neubauer P, Swanson WG, et al. (2006) Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing > 10% epidermal growth factor receptor (EGFr). J Clin Oncol 24: abstract #3548
11. J. Berlin J. Posey S. Tchekmedyian 2007 Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer Clin Colorectal Cancer 6 427 432 (Pubitemid 46658516)
12. J.R. Hecht A. Patnaik J. Berlin 2007 Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer Cancer 110 980 988 (Pubitemid 47312862)
13. Mitchell EP, Hecht JR, Baranda J, et al. (2007) Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: An updated analysis. J Clin Oncol 25: abstract #4082
14. E. Van Cutsem M. Peeters S. Siena 2007 Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapyrefractory metastatic colorectal cancer J Clin Oncol 25 1658 1664
15. (2008) Vectibix™® Prescribing Information. Amgen, Thousand Oaks, CA
16. Guideline for Clinical Evaluation of Anticancer Drugs (1991) PAB/NDD Notification No. 9; February 4, 1991
17. J.A. Lofgren S. Dhandapani J.J. Pennucci 2007 Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab J Immunol 178 7467 7472
18. E. Van Cutsem S. Siena Y. Humblet 2008 An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy Ann Oncol 19 92 98
19. P. Therasse S.G. Arbuck E.A. Eisenhauer 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216
20. (2008) Erbitux-M® Prescribing Information. Imclone Systems, Branchburg NJ
21. D. Schrag K.Y. Chung C. Flombaum 2005 Cetuximab therapy and symptomatic hypomagnesemia J Natl Cancer Inst 97 1221 1224
22. th World Congress on Gastrointestinal Cancer. 25-28 June 2008, Barcelona, Spain
23. S. Tejpar H. Piessevaux K. Claes 2007 Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study Lancet Oncol 2 387 394
24. A.R. Tan D.F. Moore M. Hidalgo 2006 Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors Clin Cancer Res 12 6517 6522
25. J. Baselga D. Pfister M.R. Cooper 2000 Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin J Clin Oncol 18 904 914
26. K.L. Wang T.T. Wu I.S. Choi 2007 Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome Cancer 109 658 667
27. M.L. Janmaat M.I. Gallegos-Ruiz J.A. Rodriguez 2006 Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients J Clin Oncol 24 1612 1619
28. S. Benvenuti A. Sartore-Bianchi F. Di Nicolantonio 2007 Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Res 67 2643 2648
29. R.G. Amado M. Wolf M. Peeters 2008 Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 1626 1634